Genmab (GMAB) Rated Outperform on Oncology Pipeline

2 weeks ago 12

Sheryar Siddiq

Sat, May 2, 2026 astatine 12:51 PM CDT 2 min read

Genmab A/S (NASDAQ:GMAB) ranks among the most profitable biotech stocks to bargain now. Wolfe Research began sum of Genmab A/S (NASDAQ:GMAB) connected March 26 with a terms nonsubjective of $32 and an Outperform rating. In anticipation of objective triggers anticipated successful 2026, the steadfast sees the existent terms dip pursuing a nonaccomplishment successful a confirmatory DLBCL survey arsenic a purchasing opportunity.

According to the firm, Genmab’s Epkinly is expected to bring successful $3.4 cardinal successful highest sales, with the frontline proceedings EPCORE DLBCL-2 being the main worth motor for the asset. Similarly, Rina-S could make $2.5 cardinal successful highest income spanning galore indications, with Wolfe anticipating findings from the RAINFOL-01 PROC this year.

Also, with respect to sales, Genmab A/S (NASDAQ:GMAB) reported that DARZALEX’s planetary nett income amounted to $3.964 cardinal successful Q1 2026. The income information see crab attraction formulas administered intravenously and subcutaneously. Net income successful the US totaled $2.208 billion, with planetary markets generating $1.756 cardinal successful revenue.

Genmab A/S (NASDAQ:GMAB) is simply a biotechnology institution specializing successful oncology, processing innovative antibody-based therapies for crab treatment. Its late-stage pipeline includes promising programs similar Rina‑S and EPKINLY.

While we admit the imaginable of GMAB arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years

Disclosure: None. Follow Insider Monkey connected Google News.

Read Entire Article